• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » X-Chem, Vertex enter genetic disease collaboration

X-Chem, Vertex enter genetic disease collaboration

May 17, 2017
CenterWatch Staff

X-Chem, a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced a collaboration with Vertex Pharmaceuticals. X-Chem will apply its proprietary DEXTM libraries, which contain more than 120 billion small molecules, toward the discovery of new drug leads against targets involved in multiple specialty diseases. Vertex will have the option to license lead-like hits discovered under the collaboration, and will be responsible for further development and commercialization of the resulting programs.

“We look forward to working closely with Vertex, a recognized innovator in discovery of first-in-class treatments for severe, life-threatening diseases,” said Rick Wagner, Ph.D., chief executive officer of X-Chem. “The combination of X-Chem’s DEXTM platform and Vertex’s expertise has great potential to generate promising leads that could lead to medicines for the treatment of serious, specialty diseases with high unmet needs.”

“As Vertex continues to grow and diversify its R&D pipeline, we look to complement our productive internal efforts with other organizations who share our passion to treat diseases for which there is no existing treatment,” said Mark Bunnage, senior vice president and Boston Research Site Head at Vertex. “With a cutting-edge small molecule lead discovery platform, X-Chem is ideally suited to help Vertex tackle challenging rare-disease targets.”

Under the terms of the agreement, X-Chem will receive an upfront payment and potential research, development and regulatory milestones and licensing fees. X-Chem is also eligible for royalties on revenues from medicines originating from the collaboration. The agreement includes the option for an expansion to include additional targets.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing